D. Boral Capital Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)
D. Boral Capital reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock. Several other equities research analysts have also recently issued reports on URGN. The Goldman Sachs Group lowered […]
D. Boral Capital reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock. Several other equities research analysts have also recently issued reports on URGN. The Goldman Sachs Group lowered […]
